Semaglutide provides double benefit for women with heart failure

FHS
June 24, 2024
5:08 pm

Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves symptoms in men and women with a common type of heart failure that has had few therapeutic options.

Meta Title: “Intellia Therapeutics Inc Patent: Genetic Modification to Reduce HLA-A Protein Expression

Share this article According to GlobalData’s company profile on Intellia Therapeutics, CRISPR genome editing was a key innovation area identified from patents. Intellia Therapeutics‘s grant

March 11, 2024

Lifestyle interventions in patients after colorectal cancer treatment

A recent RCT reveals the HEAL ABC intervention is feasible for 87% of colorectal cancer survivors, supporting healthy lifestyle changes and improved well-being.

September 4, 2024

Physicians see value in consumer drug ads, but want more financial and adherence information, survey finds

Physicians don’t hate prescription drug ads, they just want the promotions to do more. That’s according to Syneos Health’s most recent AnswerSuite survey of healthcare

July 12, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.